Eylea hd® (aflibercept) injection 8 mg positive phase 3 results in patients with macular edema following retinal vein occlusion presented at angiogenesis meeting

Eylea hd led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to eylea® (aflibercept) injection 2 mg dosed every 4 weeks eylea hd led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to eylea® (aflibercept) injection 2 mg dosed every 4 weeks
REGN Ratings Summary
REGN Quant Ranking